

AstraZeneca 

# Investor Day 2024

Unlocking growth to 2030 and beyond

## Speaker biographies





## Pascal Soriot

### Chief Executive Officer

---

Pascal is Executive Director and Chief Executive Officer at AstraZeneca. He has been a member of the Board and CEO since October 2012. Pascal has a passion for science and medicine as well as a successful track record of managing change, executing strategy and leading a diverse organisation.

Prior to AstraZeneca, Pascal served as COO of Roche's pharmaceuticals division from 2010 to 2012 and previously as CEO of Genentech where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior roles in numerous major companies around the world. He is a Doctor of Veterinary Medicine and holds an MBA from HEC Paris.

Pascal received a British knighthood for services to life sciences and leadership in the global response to the COVID pandemic in the Queen's Birthday Honours 2022. He is also on the board of the Sustainable Markets Initiative and champions the Health Systems Task Force which aims to accelerate the delivery of net zero, sustainable healthcare.





## Aradhana Sarin

### Executive Director and Chief Financial Officer

---

Aradhana is Executive Director and Chief Financial Officer at AstraZeneca. She has been a member of the Board and CFO since August 2021.

Prior to her current role, Aradhana was CFO for Alexion. Aradhana joined Alexion in 2017 and was responsible for driving strategic growth, financial performance and business development at Alexion. She brings operational experience in biopharmaceuticals plus more than 20 years of professional experience at global financial institutions and has extensive knowledge of global healthcare systems, having closed more than 100 transactions across M&A, equity and debt financing.

Before joining Alexion, Aradhana was Managing Director of Healthcare Corporate and Investment Banking at Citi Global Banking, focusing on clients in the life sciences and biopharmaceutical sectors. Aradhana trained as a medical doctor in India and spent two years practising in both India and Africa. She completed her medical training at the University of Delhi and received her MBA from Stanford Business School.

Other appointments include Aradhana is a member of the Board of Directors of the Red Cross and an independent director of



## Sharon Barr

### Executive Vice President, BioPharmaceuticals R&D

---



Sharon was appointed as Executive Vice-President, BioPharmaceuticals Research & Development in August 2023. She is responsible for discovery through to late-stage development across CVRM and Respiratory & Immunology.

Prior to this role, Sharon served as Senior Vice President, Head of Research and Product Development of Alexion, AstraZeneca Rare Disease having joined in 2013. With more than 18 years of industry experience she has previously led translational research, precision medicines, and global drug development teams.

Sharon received her PhD in molecular biology from New York University, and completed a postdoctoral fellowship focused on mechanisms of DNA Damage and Repair at Stanford University.

In 2022, Sharon was recognised as a Healthcare Businesswoman's Association Luminary in recognition of her transformational leadership and passion for mentoring those around her.





## **Ruud Dobber**

### **Executive Vice President and President, BioPharmaceuticals**

---

Ruud was appointed Executive Vice-President, BioPharmaceuticals Business Unit in January 2019 and is responsible for product strategy and commercial delivery for Cardiovascular, Renal and Metabolism, Respiratory and Immunology, and Vaccines & Immune Therapies. Prior to this, Ruud held the role of Executive Vice-President, North America and was responsible for driving growth and maximising the contribution of the commercial operations in North America.

Ruud joined Astra in 1997 and has assumed leadership roles with increasing responsibility including Executive Vice-President, North America; Executive Vice-President, Europe; Regional Vice-President, Europe, Middle East and Africa; and Regional Vice-President, Asia Pacific. Ruud served as a member of the board and executive committee of the European Federation of Pharmaceutical Industries and Associations and was previously Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America. Ruud holds a doctorate in immunology from the University of Leiden, Netherlands, beginning his career as a research scientist in immunology and ageing.





## Marc Dunoyer

### Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca

---

Marc became Chief Executive Officer of Alexion, AstraZeneca's Rare Disease group, in August 2021 following its acquisition in July 2021. He had previously served as an Executive Director and AstraZeneca's Chief Financial Officer from November 2013.

Marc's career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and, concurrently, Chairman, GSK Japan.

He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University.





## Dave Fredrickson

### Executive Vice President, Oncology Business

---

Dave was appointed Executive Vice-President, Oncology Business Unit in October 2017 and is responsible for driving growth and maximising the global commercial performance of the AstraZeneca global Oncology portfolio.

Previously, Dave served as President of AstraZeneca Japan and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association.

Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions. Prior to this, Dave worked at the Monitor Group, now Monitor Deloitte Group, a global strategy consultancy.

Dave is a graduate of Georgetown University in Washington DC.





## Susan Galbraith

### Executive Vice President, Oncology R&D

---

Susan was appointed as Executive Vice-President, Oncology Research & Development in July 2021, with responsibility for transforming the productivity and scientific output from Oncology R&D. Over her career, Susan has helped develop 12 approved medicines.

As a clinical oncologist, Susan studied medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she has been awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research, is a Fellow of the Academy of Medical Sciences and elected to the Academy of the American Association for Cancer Research.

Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021 to 2024, she also served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research Advisory Council.







## Iskra Reic

### Executive Vice President, V&I

---

Iskra is an EVP for V&I, with responsibility across the pipeline and portfolio, including R&D, medical affairs, marketing, and commercial operations. In 2021, Iskra was appointed Head of the Vaccines & Immune Therapies division, and supported the delivery of over 3bn doses of our COVID-19 vaccine to 180 countries, as well as successfully bringing to market the first pre-exposure prophylaxis monoclonal antibody to protect immunocompromised patients.

Iskra is also the Senior Executive Team sponsor of the Partnership for Health System Sustainability and Resilience and represents AstraZeneca on the PHSSR Steering Committee alongside leaders from organisations such as the London School of Economics, the World Economic Forum and the WHO Foundation.

Iskra trained as a Doctor of dental medicine at the Medical University of Zagreb, Croatia, and has a PhD in Strategy and Leadership and an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia.





## Andrew Barnett

### Vice President, Investor Relations

---

Andy is Head of Investor Relations at AstraZeneca. Andy joined AstraZeneca in 2019, initially as Global Head of Commercial for Immuno-Oncology, followed by Global Franchise Head for *Lynparza*, DDR and Established Oncology within the Oncology Business Unit.

Before joining AstraZeneca, Andy spent 11 years at Roche in roles of increasing responsibility. Most recently he was Head of Commercial for Asia Pacific. Prior to that, he worked in a variety of global and local country positions in Europe, US and Asia, including Lifecycle Leader and General Manager.

Andy holds a BSs(Hons) in Biochemistry from McGill University in Montreal and a Diploma in Marketing from the Chartered Institute of Marketing in the UK.





## Maria Belvisi

### Senior Vice President and Head of R&D Early Respiratory and Immunology

---

Maria joined AstraZeneca in 2017 from Imperial College London, where she was Professor of Respiratory Medicine. Maria is responsible for bringing early science ideas and assets from pre-clinical through to late-stage Phase III clinical trials across respiratory and immunology.

Over the last six plus years she has developed an industry-leading portfolio of early-stage assets. Maria is a world leader in the respiratory field with over 250 publications (H Index = 88). She also had a pivotal role in the development of launched drugs – LAMA's Tiotropium Bromide (*Spiriva*) and Glycopyrrolate (component of the AstraZeneca triple – *Breztri*) and the inhaled corticosteroid, *Ciclesonide*.

Her sustained excellence and leadership in the field has been recognised by the British Pharmacological Society and European Respiratory Society and in 2019 she was elected as a member of the Academy of Medical Sciences (FMedSci).





## Elisabeth Björk

### Senior Vice President, Late CVRM

---

Elisabeth is a scientific leader with more than 30 years' experience in treating patients with chronic conditions. After training as an endocrinologist, Elisabeth worked for 15 years in clinical practice and diabetes research at Uppsala University Hospital, in Sweden. Elisabeth trained at the Karolinska Institute, and is an Associate Professor in Medicine at Uppsala University. Prior to joining AstraZeneca in 2002, Elisabeth was the Head of the Diabetes and Endocrinology Unit at the Uppsala University hospital.

Elisabeth spent several years in the US as a Global Product Vice President leading the development of an SGLT2 inhibitor, and has also been involved in the delivery of other key late-phase cardiovascular and gastrointestinal projects. Elisabeth moved back to Sweden in 2014, leading the CVRM team delivering several CV outcomes studies.

Elisabeth serves as a Board Member at Chalmers University of Technology, Chalmers Ventures, Rocket Pharmaceuticals and Björks Matematik & Mera.





## Caterina Brindicci

### Senior Vice President, Late R&I

---

As Senior Vice President & Global Head for Late Respiratory & Immunology, Caterina leads a team of more than 500 across seven countries globally with accountability for the exciting late clinical development portfolio, advancing potential medicines from Phase IIb/III through to submission and approval, and subsequently into life cycle management.

A pulmonologist with a PhD in Clinical Pharmacology and an MBA, Caterina blends clinical expertise, business acumen, and a passion for improving patients' lives. Her transformation of clinical trial design has resulted in landmark Phase III trials with the potential to revolutionise clinical guidelines and transform care.

Caterina was previously the Global Franchise Head of AstraZeneca's Inhaled Products. She joined AstraZeneca from Novartis, where she was Clinical Development Head for the Respiratory & Allergy Development Unit. Caterina has 15 years of experience in senior roles across the pharmaceutical industry and was a Clinical Researcher at the National Heart & Lung Institute, Imperial College, and the Royal Brompton Hospital, London.





## Robert Chen

### Global Head of Lymphoma and Head of Clinical Development, Oncology R&D

---

Based in Cambridge, Robert is the Global Head of Lymphoma and Head of Clinical Development in AstraZeneca Haematology R&D.

Dr Chen previously held the position of Executive Medical Director at Autolous Therapeutics, leading the CART cell development in Lymphoma.

Prior to transitioning to industry, Robert was the Associate Director of the Stephenson Lymphoma Center and Lymphoma Disease Head at City of Hope Medical Center where he led phase 1-3 clinical trials for more than ten years.





## Seng Cheng

### Senior Vice President, Head of Research and Product Development, Alexion

---

Seng is responsible for drug discovery, process development and clinical supply as well as clinical biomarkers and bioanalytical discovery, rare disease diagnostics and bioinformatics, supporting Alexion's pipeline from target discovery through post-marketing.

Seng was previously Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer. Prior to joining Pfizer, he held roles including Group Vice President of Genetic Diseases Science at Genzyme as well as the Global Head of Research of Rare Diseases at Sanofi. He has contributed to the development of several medicines for patients with rare diseases, co-authored over 280 research articles and reviews and is a named co-inventor on 64 issued US patents in the area of biotechnology.

Seng obtained his BSc and PhD degrees in Biochemistry at the University of London and trained as a postdoctoral fellow in the field of tumor biology at the National Institute of Medical Research, UK.





## **Mark Cobbold**

### **Senior Vice President, IO Discovery and Cell Therapy**

---

Mark Cobbold is Senior Vice President of IO Discovery and Cell Therapy at AstraZeneca and is responsible for the basic science and early drug development in cell therapy, immuno-oncology and immune engagers.

Mark is an immunologist and joined AstraZeneca from Massachusetts General Hospital in 2019 where he was an Associate Professor of Medicine at Harvard Medical School with an interest in immunotherapy for cancer. His research identified included tumour antigens, novel cell engineering approaches as applied to cancer, and T cell engaging biotherapeutics. He is the inventor of a number of platform technologies (APEC, TEAC).

Previously, Mark was a Medical Research Council Clinician Scientist and undertook his PhD training in cell therapy. He is passionate about innovation co-founding a number of spin-out companies before he joined AstraZeneca including SeraScience (acquired by Abingdon Heath), PhosImmune (acquired by Agenus), Revitope Oncology, Gritstone Oncology and C-Reveal Therapeutics (now Gyges Oncology).







## **Martin Cowie**

### **Interim Senior Vice President, Late-Stage Development, CVRM**

---

Professor Martin Cowie, Therapy Area Head for Late Stage CVRM, joined AstraZeneca full-time two years ago after a 25-year career as a clinical academic cardiologist at Imperial College London where he led the advanced heart failure service at the Brompton Hospital during that time.

He has a longstanding interest in drug and device development, and has been instrumental in moving science into new medicines in cardiovascular disease throughout his career. He has also trained in epidemiology and statistics, and was a Non-Executive Director on the Board of NICE (the gateway to reimbursement in England) from 2018-2022.

Martin was the Inaugural Chair of the European Society of Cardiology Digital Health Committee from 2018-2022. He has published more than 400 scientific papers and has an h-index of 98.





## Regina Fritsche Danielson

### Senior Vice President and Head of R&D Early CVRM

---

Associate Professor, Dr Regina Fritsche-Danielson is accountable for the small and large molecule as well as new modalities research and development from early target discovery to Phase III investment decision, with a research strategy focused on three key areas with high unmet medical need, cardiovascular diseases including heart failure and dyslipidaemia, metabolic diseases including obesity, diabetes and liver disease and renal diseases.

Regina has a PhD in Cardiovascular Physiology/Pharmacology at the University of Göteborg in 1993. During her academic years Regina worked at the University of Göteborg, University of Ottawa, University of Queensland and University of Nevada. In 2001, Regina joined AstraZeneca and has held various leadership positions and strategic roles as well as led drug projects in discovery and early development phase.





## Mark Esser

### Vice President, Early V&I R&D

---

Mark joined AstraZeneca in 2010 and is currently Vice President of Vaccines and Immune Therapies early R&D. He is responsible for all antibody and vaccine discovery, research and translational medicine for AstraZeneca's infectious disease programs bringing early science ideas from the concept to the clinic.

In response to the COVID-19 pandemic, Mark led AstraZeneca's COVID-19 monoclonal antibody program and supported R&D efforts for the authorisation of the AstraZeneca COVID-19 vaccine.

Prior to joining AstraZeneca, he was the director of the Vaccine and Biologics Center of Excellence at Pharmaceutical Product Development (PPD) and prior to PPD he was at Merck Vaccines where he was instrumental in the approval of *Gardasil*<sup>®</sup> for the prevention of cervical cancer.

Mark received his B.S. in biochemistry from Case Western Reserve University, his doctorate in microbiology and immunology from University of Virginia and did his postdoctoral fellowship at the AIDS vaccine program at the National Institutes of Health.





## Nicola Heffron

### Senior Vice President, Head of Global Marketing and Market Access, Alexion

---

Nicola leads Alexion's Global Marketing and Market Access team focused on global marketing, global commercial strategy, pricing and market access. Prior to joining Alexion, Nicola served as the Chief Operating Officer at 2seventybio, a spin out of bluebird bio.

Nicola has more than 25 years of experience across the pharmaceutical and biotech industries, primarily in the rare disease and oncology space, including positions with Celgene, Shire, GSK and Lilly.

Nicola holds a Bachelor of Pharmacy degree from Bradford University in the U.K. and an MBA from Warwick University.





## Matt Hellmann

### Vice President, Early Oncology Development

---

Matthew Hellmann, MD, is Vice President, Early Oncology Development, at AstraZeneca. In this role, he is responsible for the strategic planning and execution of the early oncology portfolio, as well as translational medicine and cancer biomarker discovery.

Matt is a medical oncologist, and received his MD from Johns Hopkins University, completed residency training at Massachusetts General Hospital, and medical oncology fellowship at Memorial Sloan Kettering.

Matt was previously a clinical investigator at Memorial Sloan Kettering Cancer Center in New York, USA, focusing on the treatment of patients with lung cancer, early drug development related to immunotherapies, and translational research examining biomarkers of response.





## Leora Horn

### Global Clinical Head for Lung Cancer and Lung Cancer Strategy, Oncology R&D

---

At AstraZeneca, Leora is responsible for leading global research and development efforts in lung cancer, partnering with lung cancer teams across AstraZeneca to rapidly progress research and deliver on a broader commitment to treat and potentially cure more patients globally with the disease.

Leora has served as principal investigator on several national and global lung cancer trials for immunotherapies, targeted therapies and novel treatments across early- and late-stage development and has published more than 150 papers and book chapters. She is also an active member and served on the scientific committees of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.

Prior to completing a subspecialty fellowship in thoracic oncology at Vanderbilt University, Leora earned a medical degree from University of Toronto and received a Bachelor of Science and a Master of Science in Pharmacology.





## Mina Makar

### Senior Vice President, Global CVRM

---

Mina leads the US marketing, sales and access strategy for AstraZeneca's Respiratory & Immunology therapeutic area and is a member of the US Leadership Team.

Since joining AstraZeneca in 1999, Mina has held roles in the US and globally. Most recently, he served as Executive Director, Biologics Marketing, and earlier as Executive Director, Inhaled Marketing. Prior to joining the US Respiratory team in 2016, Mina held roles of increasing responsibility across the US and Global commercial organisation including Field Sales and Marketing.

Prior to joining AstraZeneca, Mina practiced pharmacy and worked in medical affairs and national account sales for Upsher-Smith Laboratories in Minnesota.

Mina was trained as a pharmacist at the Pharmacy Drake University, Des Moines, Iowa.





## **Cristian Massacesi**

### **Chief Medical Officer and Oncology Chief Development Officer**

---

Appointed in 2021, Cristian leads AstraZeneca's late-stage Oncology portfolio through global clinical development and regulatory submissions. Cristian also leads patient safety and quality assurance activities for the entire portfolio. Over his career, Cristian has helped develop more than a dozen approved medicines.

Before joining AstraZeneca, Cristian held a variety of clinical development leadership roles at Pfizer and at Novartis Pharmaceuticals. He has lectured extensively on oncology clinical development, has authored over 50 peer-reviewed publications, and has generated several patents for cancer treatment combinations and regimens.

A medical oncologist by training, Cristian earned his medical degree from Marche Polytechnic University and received Medical Oncology training at the Royal Marsden Hospital, Kaplan Comprehensive Cancer Center and the European Institute of Oncology.







## Ingrid Mayer

### Vice President, Global Clinical Strategy Head, Breast and Gynecologic Cancers, Oncology R&D

---

Appointed in 2021, Ingrid, a breast medical oncologist, is responsible for organising and leading strategic planning efforts, decision-making and initiatives aimed at defining and developing the ongoing and future directions of breast and gynecological cancers.

Prior to joining AstraZeneca, Ingrid was a Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt University Medical Center for 18 years. Her translational research endeavors were focused on the identification of targetable pathways in breast cancer and mechanisms of resistance to breast cancer therapies, and have been funded by the NCI, SU2C/ AACR, Susan G. Komen Foundation and the Breast Cancer Research Foundation.

She was the Chair of the Endocrine Therapy Working Group of the Translational Breast Cancer Research Consortium, and the Vanderbilt representative in the ECOG-ACRIN Breast Core Committee and the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts.





## Pablo Panella

### Senior Vice President, Global R&I

---

As Senior Vice-President, Global Respiratory & Immunology, Pablo is responsible for AstraZeneca's global R&I business and strategy for the Company's current and future R&I portfolio of medicines.

Prior to his current role, Pablo was Senior Vice-President of the Western and Southern Europe Area, responsible for a cluster of nine European countries and in charge of Europe and Canada's Regional Commercial teams.

During his tenure at AstraZeneca Pablo has held several senior manager positions, including those of Oncology Business Head in Spain, Commercial Director in the UK, and Country President for AstraZeneca Italy.

Pablo holds a BSc in Business from Austral University in Argentina, where he was born and has a dual citizenship (Argentinean/ Italian). He joined AstraZeneca in 2008 after completing his MBA in the Institute of Management Development in Lausanne, Switzerland, in 2007.





## **Gianluca Pirozzi**

### **Senior Vice President, Head of Development and Safety, Alexion**

---

Gianluca joined Alexion in October 2019 and currently leads the company's integrated Development, Regulatory and Safety organisation. Previously, he served in various roles at Sanofi Genzyme, including Head of Development for Rare Diseases and Gene Therapy.

Gianluca has served on the Board of Directors of Imbria Pharmaceuticals for two years, and is currently Board Member of Timber Pharmaceuticals, as well as scientific advisor for the Smith-Magenis Syndrome Research Foundation.

Gianluca holds an MD degree from University Campus Bio-Medico and a PhD in Immunology from Sapienza University, both in Rome, Italy, and completed a Post-Doctoral Research Fellowship in Immunology at the Pasteur Institute in Paris, France.





## Osama Rahma

### Vice President, Global Clinical Strategy Head, GI Oncology, Oncology R&D

---

Osama is a Gastrointestinal Oncologist, appointed in 2021 to lead AstraZeneca Strategy in GI Oncology. He is responsible for the late clinical development across all GI Cancers.

Prior to joining AstraZeneca, Osama spent his academic career in Cancer Immunotherapy and GI Oncology drug development. He was the Clinical Director of the Center for Cancer Therapeutic Innovation at Dana-Farber Cancer Institute and Harvard Medical School.

Osama received his medical degree from University of Damascus and completed an Immunology and GI Oncology fellowship at the National Cancer Institute/NIH.

He established the Immuno-Toxicity Program at Brigham and Women Hospital, served as the co-director of the Hepatobiliary and Pancreatic Cancer Program at University of Virginia and authored over 100 peer-reviewed articles and book chapters.





## Puja Sapra

### Senior Vice President, Biologics Engineering and Oncology Targeted Discovery

Puja is the Senior Vice President of the Biologics Engineering & Oncology Targeted Discovery. In this role, she leads the discovery groups responsible for development of tumor-targeting modalities including Antibody Drug Conjugates, radioconjugates and small molecules for Oncology Research. She also leads discovery efforts of all biologics for AstraZeneca.

Prior to joining AstraZeneca, Puja was Vice President and Chief Scientific Officer at Pfizer Inc., where she built platforms and a diversified pipeline of tumor-targeted biologics including ADCs, T-cell engagers and conditional biologics.

She is a world-renowned expert in the ADC arena and has given numerous plenary talks at national and international meetings. Notable successes include contributing to three approved ADCs (*Mylotarg*, *Besponsa*, *Trodelvy*), and CD3-bispecific (*Elrexfio*) as well as progressing several others in the clinic. She has authored over 50 scientific publications, book chapters and is a named inventor/co-inventor on more than 25 patents. She serves as Deputy Editor of Molecular Cancer Therapeutics and was awarded HBA Rising Star in 2017 and Long-Standing Contribution to the Field Award at World ADC conference in 2023.





## Nina Shah

### Global Clinical Head, Multiple Myeloma

---

Nina joined AstraZeneca in July 2022 as the Global Clinical Head of Multiple Myeloma Clinical Development and Strategy. Dr Shah's career has focused on early and late phase trials on immunotherapy and patient experience in multiple myeloma.

Prior to joining AstraZeneca, Dr Shah was Clinical Professor of Medicine at University of California San Francisco, where she still sees patients. She has served as a principal investigator for numerous CAR-T trials as well as studies on autologous transplant, adoptive natural killer cell therapy and dendritic cell vaccine therapy. She has also served as the chair of the Scientific Committee on Plasma Cell Disorders for the American Society of Hematology.

Nina completed her undergraduate degree in cognitive neuroscience at Harvard University and received her M.D. from New York University. She then trained in internal medicine at Columbia University and completed her hematology-oncology fellowship at M.D. Anderson Cancer Center.



# Sunil Verma

## Senior Vice President, Global Medical Affairs

---

Sunil Verma is Global Head of Oncology, Medical in AstraZeneca. His leadership is focused on advancing the practice of cancer care through robust evidence generation to address unmet needs, scientific partnerships and redefining the future cancer care paradigm.

Before joining AstraZeneca in August 2019, Dr Verma was a Medical Oncologist, provided clinical care and expertise with a focus in breast and lung cancer and held several pivotal leadership and research roles in academic medicine over 15 years.

He served as Professor and Head of the Department of Oncology at the University of Calgary and the Medical Director of the Tom Baker Cancer Centre from 2015-2019. He also served on faculty at University of Toronto as Associate Professor and Medical Director of the Breast Cancer Centre at Sunnybrook, Toronto. Over the past two decades, he has helped to develop and shape the care of breast cancer clinical care with significant contribution across many classes of drugs including Immunotherapy, CDK4/6-Is and ADCs.





## Anas Younes

### Senior Vice President, Global Head of Haematology, Oncology R&D

---

Anas joined AstraZeneca in 2020 as the Senior Vice President, Global Head of Haematology (Early and Late Stage). As a trained clinician-scientist, Dr Younes has spent more than 25 years caring for patients with lymphoma.

Prior to joining AstraZeneca, Dr Younes was at Memorial Sloan Kettering Cancer Center where he served as the Chief of the Lymphoma Service, in addition to leading a laboratory focused on drug development for patients with lymphoid malignancies.

Prior to MSKCC, Dr Younes worked for 20 years at University of Texas MD Anderson Cancer Center (MDACC) where he directed clinical and translational research in the Department of Lymphoma and Myeloma.

